Eyenovia falls after plans to merge with private firm Betaliq
Shares of eye-disease focused Eyenovia EYEN.O fall 2.4% to $1.63 premarket
Co says it is exploring a reverse merger with privately held Betaliq to combine their eye-disease focused operations
The proposed deal values Betaliq at around $77 million and Eyenovia at about $15 million
EYEN will hold 16.3% of the combined company and Betaliq will hold the remaining stake, if merger is successful
Both EYEN's Optejet device and Betaliq's EyeSol technology are used to deliver FDA-approved eye-care medications to patients
Up to last close, EYEN fell ~2x in the past 12 months
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Precious Metals May Outlook: After U.S.-Iran Conflict Concerns Eased, Will Funds Flow Back to Gold and Silver?

Is SanDisk the Hidden Gem of the AI Boom in 2026? Discover the Potential Risks and Rewards.

Intel vs. TSM: Which Semiconductor Stock Looks Like the Better Investment?

What Is Intel, and Is Its Stock Still a Worthwhile Investment?

Amazon vs. Microsoft: Which Stock Is a Better Buy for 2026 and Beyond?

Tradingkey








